SXTP 60 DEGREES PHARMACEUTICALS,...

Nasdaq 60degreespharma.com


$ 1.50 $ -0.04 (-2.91 %)    

Thursday, 16-Oct-2025 16:16:53 EDT
QQQ $ 598.70 $ -2.23 (-0.37 %)
DIA $ 459.00 $ -3.15 (-0.68 %)
SPY $ 659.11 $ -4.53 (-0.68 %)
TLT $ 91.34 $ 0.68 (0.75 %)
GLD $ 401.20 $ 9.06 (2.34 %)
$ 1.5
$ 1.58
$ 1.48 x 225
$ 1.51 x 1
$ 1.49 - $ 1.59
$ 1.22 - $ 12.45
221,875
na
2.21M
$ 2.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-20-2023 09-30-2023 10-Q
9 08-25-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 60-degrees-pharmaceuticals-says-the-first-patient-who-completed-the-regimen-in-expanded-access-study-of-arakoda-tafenoquine-combined-with-conventional-treatments-for-relapsing-babesiosis-in-immunosuppressed-patients-has-tested-negative-for-babesiosis

Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 to...

 60-degrees-pharma-launches-b-free-study-first-ever-trial-for-chronic-babesiosis-treatment

 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60 Degrees Pharma" or the "Company"), a pharmaceutic...

 ascendiant-capital-maintains-buy-on-60-degrees-lowers-price-target-to-3

Ascendiant Capital analyst Lucas Ward maintains 60 Degrees (NASDAQ:SXTP) with a Buy and lowers the price target from $7 to $3.

 60-degrees-pharma-signs-clinical-trial-agreement-with-icahn-school-of-medicine-at-mount-sinai-in-new-york-city-as-central-site-for-phase-ii-clinical-study-of-tafenoquine-in-treating-chronic-babesiosis

90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to b...

 60-degrees-q2-eps-125-misses-096-estimate-sales-101000k-miss-301000k-estimate

60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(0.96) ...

 60-degrees-pharma-prices-public-offering-of-263m-shares-and-warrants-at-a-combined-offering-price-of-190-potential-additional-5m-from-warrant-exercise

60 Degrees Pharmaceuticals, Inc. (the "Company" or "60 Degrees") (NASDAQ:SXTP, SXTPW))), a pharmaceutical compa...

Core News & Articles
Market-Moving News for July 15th
07/15/2025 11:15:22

TTD: 16% | The Trade Desk Will Replace Ansys In The S&P 500 Effective Prior To The Opening Of Trading On Friday, July 18 XA...

 60-degrees-pharmaceuticals-announces-the-company-will-conduct-a-gap-analysis-of-its-existing-data-prior-to-submitting-a-minor-use-minor-species-designation-request-to-the-us-fda-for-tafenoquine-for-the-treatment-of-acute-canine-babesiosis

Data from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosisWASHINGTON, Jul...

 60-degrees-pharmaceuticals-launches-new-8-count-bottle-format-of-arakoda

New 8-count bottles now available through major retail pharmaciesARAKODA® is the only weekly prophylactic therapy to provide pr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION